RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nuo Therapeutics Stock

Nuo Therapeutics Revenue 2025

Nuo Therapeutics Revenue

608,530 USD

Ticker

AURX

ISIN

US67059V2097

WKN

A2AP5P

In 2025, Nuo Therapeutics's sales reached 608,530 USD, a 453.21% difference from the 110,000 USD sales recorded in the previous year.

The Nuo Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
20230.6179,28
20220.1181,82
2021--
2020--
20190.1520,00
20181.3788,32
20170.72-51,39
20162.226,82
201511.5130,76
20147.7612,76
201311.5726,97
201210.5662,97
20117.2562,34
20103.9158,82
20092.0777,78
20082.0971,29
20071.9456,19
20061.9548,21
20051.5241,45
20041.1537,39

Nuo Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nuo Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nuo Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nuo Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nuo Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nuo Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nuo Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nuo Therapeutics’s growth potential.

Nuo Therapeutics Revenue, EBIT and net profit per share

DateNuo Therapeutics RevenueNuo Therapeutics EBITNuo Therapeutics Net Income
2023608,530 undefined-3.17 M undefined-3.17 M undefined
2022110,000 undefined-3.32 M undefined-3.17 M undefined
20210 undefined-90,000 undefined-890,000 undefined
20200 undefined-380,000 undefined7.71 M undefined
2019150,000 undefined-970,000 undefined-1.19 M undefined
20181.37 M undefined-1.5 M undefined-1.54 M undefined
2017720,000 undefined-6.23 M undefined-14.98 M undefined
20162.2 M undefined-8.31 M undefined22.48 M undefined
201511.51 M undefined-14.27 M undefined-52.81 M undefined
20147.76 M undefined-18.71 M undefined-18.88 M undefined
201311.57 M undefined-18.1 M undefined-20.25 M undefined
201210.56 M undefined-12.37 M undefined-19.81 M undefined
20117.25 M undefined-3.52 M undefined-3.86 M undefined
20103.91 M undefined-5.4 M undefined-9.04 M undefined
20092.07 M undefined-3.45 M undefined-3.27 M undefined
20082.09 M undefined-4.35 M undefined-7.68 M undefined
20071.94 M undefined-5.35 M undefined-5.07 M undefined
20061.95 M undefined-3.91 M undefined-2.04 M undefined
20051.52 M undefined-7.35 M undefined-6.49 M undefined
20041.15 M undefined-8.24 M undefined-11.31 M undefined

Nuo Therapeutics stock margins

The Nuo Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nuo Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nuo Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nuo Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nuo Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nuo Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nuo Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nuo Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nuo Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nuo Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nuo Therapeutics Margin History

Nuo Therapeutics Gross marginNuo Therapeutics Profit marginNuo Therapeutics EBIT marginNuo Therapeutics Profit margin
202379.28 %-520.64 %-521.16 %
202281.82 %-3,018.18 %-2,881.82 %
202179.28 %0 %0 %
202079.28 %0 %0 %
201920 %-646.67 %-793.33 %
201888.32 %-109.49 %-112.41 %
2017-51.39 %-865.28 %-2,080.56 %
201626.82 %-377.73 %1,021.82 %
201530.76 %-123.98 %-458.82 %
201412.76 %-241.11 %-243.3 %
201326.97 %-156.44 %-175.02 %
201262.97 %-117.14 %-187.59 %
201162.34 %-48.55 %-53.24 %
201058.82 %-138.11 %-231.2 %
200977.78 %-166.67 %-157.97 %
200871.29 %-208.13 %-367.46 %
200756.19 %-275.77 %-261.34 %
200648.21 %-200.51 %-104.62 %
200541.45 %-483.55 %-426.97 %
200437.39 %-716.52 %-983.48 %

Nuo Therapeutics Aktienanalyse

What does Nuo Therapeutics do?

Nuo Therapeutics Inc is a US-American company specializing in the development and marketing of medical products and therapies for wound healing. The company was originally founded in 2002 as Cytomedix and was renamed Nuo Therapeutics in 2016. The company's history stems from the discovery of growth factors produced by human platelets, which play an important role in wound healing. Research has shown that these growth factors can be used to expedite wound healing, making it a promising approach for the development of new medical therapies. Nuo Therapeutics aims to develop and bring innovative wound healing products and therapies to the market. The company specializes in three main areas: biosurgery, dermatology, and advanced wound care. In the biosurgery division, Nuo Therapeutics offers a range of medical products that can be used for hemostasis and wound care. This includes Nexagon® Gel, a wound treatment product based on the aforementioned growth factors, and SurgiWrapTM, a barrier membrane for the protection of surgically treated soft tissues. In the dermatology division, Nuo Therapeutics focuses on the development of therapeutic products for the treatment of skin conditions such as eczema, psoriasis, and acne. To this end, the company has entered into an agreement with a leading pharmaceutical company to develop the skincare product SECUAADTM. The advanced wound care division of Nuo Therapeutics focuses on the treatment of difficult, chronic wounds that do not heal. In this area, the company has acquired the rights to a unique technology called AurixTM, which is based on the use of growth factors from the patient's own blood. With AurixTM, Nuo Therapeutics aims to help patients with hard-to-heal wounds heal their wounds faster and more safely. The business model of Nuo Therapeutics is based on the development and commercialization of innovative medical products and therapies. The company relies on partnerships with other companies in the pharmaceutical and medical industries to support the development and marketing of its products. Nuo Therapeutics has experienced strong growth in recent years and has established itself as a key player in the market for medical wound healing products. With its innovative products and therapies, the company is well positioned to continue growing in the future and make a significant contribution to improving medical care for patients worldwide. Nuo Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Nuo Therapeutics's Sales Figures

The sales figures of Nuo Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Nuo Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Nuo Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Nuo Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Nuo Therapeutics stock

How much revenue did Nuo Therapeutics generate this year?

Nuo Therapeutics has achieved a revenue of 608,530 USD this year.

How much was the turnover of the company Nuo Therapeutics compared to the previous year?

The revenue of Nuo Therapeutics has increased by 453.21% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Nuo Therapeutics?

The revenue of Nuo Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Nuo Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Nuo Therapeutics so important for investors?

The revenue of Nuo Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Nuo Therapeutics pay?

Over the past 12 months, Nuo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuo Therapeutics?

The current dividend yield of Nuo Therapeutics is .

When does Nuo Therapeutics pay dividends?

Nuo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuo Therapeutics?

Nuo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nuo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuo Therapeutics located?

Nuo Therapeutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nuo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuo Therapeutics from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Nuo Therapeutics pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Nuo Therapeutics in the year 2024?

In the year 2024, Nuo Therapeutics distributed 0 USD as dividends.

In which currency does Nuo Therapeutics pay out the dividend?

The dividends of Nuo Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nuo Therapeutics

Our stock analysis for Nuo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.